This functionality is implemented using Javascript. It cannot work without it, etc...

Estamos cargando la información...

Saltar al contenido

Chimeric Antigen Receptor Therapy for Multiple Myeloma

Idecabtagene vicleucel may be considered medically necessary for patients with multiple myeloma if they meet criteria 1 through 6:
Are adults (age ≥18) at the time of infusion

Have a documented diagnosis of multiple myeloma

Have relapsed or refractory disease after 4 or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody (see Policy Guidelines)

Have adequate organ and bone marrow function as determined by the treating oncologist/hematologist

Does not have active infection(s) or inflammatory disorders

Have not received prior chimeric antigen receptor T therapy or any other gene therapy or are being considered for treatment with any other gene therapy.

787-277-6653 787-474-6326